Post-stroke cognitive impairment can limit rehabilitation, independence, and quality of life after ischemic stroke. This pilot randomized controlled trial evaluates whether mesenchymal stem cell-derived secretome, given in addition to standard stroke care and rehabilitation, improves cognitive recovery in patients with subacute ischemic stroke. Participants aged 40 to 75 years with ischemic stroke occurring 7 days to 3 months previously and mild-to-moderate cognitive impairment will be randomly assigned in a 1:1 ratio to receive standard care and rehabilitation plus MSC secretome or standard care and rehabilitation without MSC secretome. The primary outcome is the change in the Indonesian version of the Montreal Cognitive Assessment score. Secondary outcomes include quantitative electroencephalography parameters, serum brain-derived neurotrophic factor, serum interleukin-1β, NIHSS, modified Rankin Scale, and adverse events.
Inclusion Criteria:
Exclusion Criteria:
tejayanovi@gmail.com+6282188833368
Outcome assessors responsible for the MoCA-Ina, NIHSS, modified Rankin Scale, and quantitative electroencephalography assessments are blinded to treatment allocation. The randomization sequence and treatment assignment are not disclosed to the outcome assessors
Participants receive standard medical treatment and standardized stroke rehabilitation plus umbilical cord mesenchymal stem cell-derived secretome. The secretome intervention is administered according to the study protocol, with safety monitoring during and after administration.
Participants receive standard medical treatment and standardized stroke rehabilitation without MSC secretome.
Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct
UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX)
Clinical Trial of Umbilical Cord Mesenchymal Stem Cells in Subacute Ischemic Stroke
Clinical Plan of Ischemic Stroke
Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke
Autologous Bone Marrow Mesenchymal Stem Cell Therapy for Ischemic Stroke
Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral Stroke
Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke